Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Tenapanor Hits Mark in Japan Hyperphosphatemia Study: Kyowa Kirin
Kyowa Kirin said on December 13 that its selective sodium-hydrogen exchanger 3 (NHE3) inhibitor tenapanor hit the primary endpoint in a Japan PIII trial for the treatment of hyperphosphatemia in patients on hemodialysis. The double-blind and placebo-controlled study assessed the…
To read the full story
Related Article
- Kyowa Kirin Files Hyperphosphatemia Drug in Japan
October 31, 2022
- Kyowa Kirin Commences Japan PIII of NHE3 Inhibitor for Hyperphosphatemia
April 14, 2021
- Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII
June 10, 2020
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
- Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
November 29, 2017
BUSINESS
- Roche Proposes Ex-Takeda CEO Weber for Board
September 24, 2026
- Astellas Starts Setidegrasib PIII in KRAS G12D-Mutated NSCLC
September 24, 2026
- Otsuka’s Antisense Drug Hits PIII Goal in FUS-ALS
September 24, 2026
- EU Panel Backs Enhertu for Adjuvant Use in HER2-Positive Breast Cancer
September 24, 2026
- Moderna Launches XFG-Updated mNEXSPIKE in Japan
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…